A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test how safe and effective the research study drug,
pembrolizumab is as a treatment for patients with Hodgkin lymphoma who have not previously
been treated for this disease and are unsuitable for standard treatment (adriamycin,
bleomycin, vinblastine, dacarbazine ABVD).